Treatment of peri-implant mucositis; A randomized placebo controlled clinical study - Treatment of peri-implant mucositis

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1) The patient is >=18 years of age;
•2) The patient has at least one endosseous implant in the oral cavity with clinical signs of peri-implant mucositis. Peri-implant mucositis is defined as bleeding of the peri-implant mucosa on probing, with no signs of loss of supporting bone;
•3) The implants have been exposed to the oral environment for at least one year;
•4) The patient is capable of understanding and giving informed consent.

•1) Medical and general contraindications for the interventions;
•2) A history of local radiotherapy to the head and neck region;
•3) Diabetes;
•4) Patients who are allergic to chlorhexidine;
•5) Systemic use of antibiotics during the last 3 months;
•6) Long-term use of anti-inflammatory drugs;
•7) Incapability of performing basal oral hygiene measures as a result of physical or mental disorders;
•8) Active, uncontrolled periodontal pathology of the remaining dentition.
•9) Local use of antibiotics or use of other anti-septic / antimicrobial therapies in the oral cavity during the last 3 months;
•10) Use of mouthrinses during the last 6 weeks or during the course of the study;
•11) Implants placed in skin grafted areas;
•12) Peri-implantitis;
•13) Implant mobility;
•14) Implants at which no surface can be identified where proper probing measurements can be performed;
•15) Previous treatment of peri-implant mucositis lesions during the last 6 months.

发起方